The Longevity Fund

The Longevity Fund

Deming established The Longevity Fund in 2013, formalizing a mission she had pursued since childhood — she skipped college to work in Cynthia Kenyon's lab, studied the biology of aging, and was accepted to the Thiel Fellowship before launching the firm. The Longevity Fund operates from San Francisco as a pure-play venture capital vehicle, making seed and early-stage investments in biotechnology companies that target the underlying mechanisms of aging rather than individual age-related diseases. The firm's structural distinctiveness lies in its narrow mandate: it does not deviate into general healthcare or broader biotech, maintaining a concentrated portfolio built around a single scientific conviction. The firm's investment strategy centers on early-stage, platform-oriented longevity science. Asset classes are limited to private biotech equity, with capital deployed through direct seed and Series A investments. The fund's geographic scope concentrates on US-based companies, though Deming has evaluated opportunities globally through her advisory work and the Longevity Fund's network. Confirmed portfolio companies include Unity Biotechnology, which went public in 2018 with a focus on senolytics, and Catalog, a startup developing DNA-based data storage with implications for biological computing interfaces (per public filings and press reports). The fund also participated in early rounds for Loyal, a company working on lifespan extension for companion dogs (per the firm's official communications). Deming often structures these investments with a 10-to-20-year return horizon, aligning capital with the lengthy development cycles inherent to aging science. The Longevity Fund has not disclosed total assets under management or its full team headcount publicly. The operation is lean, centered on Deming's leadership and a network of scientific advisors rather than a multi-layered investment staff. The firm has not launched adjacent vehicles, philanthropic foundations, or club-membership-style co-investor networks under its own banner. In recent years, Deming has expanded the firm's public-facing work through The Longevity Fund's writing and her involvement in broader conversations about longevity science, but no new fund closes or major structural changes have been publicly confirmed since 2020. The fund's structural differentiator is its founding thesis: it was constructed to treat longevity as an engineering discipline rather than a speculative biotech sub-sector. Unlike larger life-science venture firms where aging is one allocation among many, The Longevity Fund's entire portfolio and partner network exist to solve a single problem. This focus shapes its deal selection, its willingness to back pre-Phase I science, and its tolerance for clinical timelines that exceed standard fund lifecycles — a posture that remains rare even within the growing longevity investment space.